Brain Advance Access originally published online on August 13, 2007
Brain 2007 130(10):2607-2615; doi:10.1093/brain/awm191
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PIB is a non-specific imaging marker of amyloid-beta (Aß) peptide-related cerebral amyloidosis
1GlaxoSmithKline, Clinical Science & Technology, CPDM and NGI-CEDD, NFSP North, Third Avenue, Harlow, Essex, CM19 5AW, UK, 2Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG, UK, 3Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, 4Maricopa Integrated Health System, 2601 East Roosevelt Street, Phoenix, AZ 85008, USA and 5Department of Neurology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
Correspondence to: A. Lockhart, Clinical Science & Technology, Neurology-CPDM, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK E-mail: Andrew.2.Lockhart{at}gsk.com
The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer's disease (AD) and to date has been assumed to bind with high affinity and specificity to the amyloid structures associated with classical plaques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investigated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during in vivo imaging scans. Using a combination of autoradiography and histochemical techniques, we demonstrate that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy (CAA). The interaction of PIB with CAA was not fully displaceable and this may be linked to the apolipoprotein E-
4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was markedly lower than that associated with the amyloid-beta (Aß) pathology. The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Aß-peptide related cerebral amyloidosis.
Key Words: PIB; amyloid; Alzheimer's disease; positron emission tornography; imaging
Abbreviations: AD, Alzheimer's disease; ApoE, apolipoprotein E; Aß, amyloid-beta peptide; BTA-1, 2-(4'-methylaminophenyl)benzothiazole; CAA, cerebrovascular amyloid angiopathy; CAA-NDB, CAA-associated non-displaceable binding; CPs, classical plaques; DLB, dementia with Lewy bodies; DPs, diffuse plaques; ECX, entorhinal cortex; FDDNP, 2-(1-{6-[(2-fluoroethyl(methyl)amino]-2-naphthyl}ethylidene)malononitrile; FTD, frontotemporal dementia; MFG, mid-frontal gyrus; NFTs, neurofibrillary tangles; NDB, non-displaceable binding; OCL, occipital lobe; PET, positron emission tomography; PIB, Pittsburgh Compound-B (2-[4'-(methylamino)phenyl]-6-hydroxybenzothiazole); rCMRglc, regional cerebral glucose metabolism rate; SB13, 4-N-methylamino-4'-hydroxystilbene; SPL, superior parietal lobe; SPs, senile plaques
Received April 27, 2007. Revised July 12, 2007. Accepted July 23, 2007.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. E. Smith and S. M. Greenberg {beta}-Amyloid, Blood Vessels, and Brain Function Stroke, July 1, 2009; 40(7): 2601 - 2606. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Mormino, J. T. Kluth, C. M. Madison, G. D. Rabinovici, S. L. Baker, B. L. Miller, R. A. Koeppe, C. A. Mathis, M. W. Weiner, W. J. Jagust, et al. Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects Brain, May 1, 2009; 132(5): 1310 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Jack Jr, V. J. Lowe, S. D. Weigand, H. J. Wiste, M. L. Senjem, D. S. Knopman, M. M. Shiung, J. L. Gunter, B. F. Boeve, B. J. Kemp, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain, May 1, 2009; 132(5): 1355 - 1365. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Drzezga, T. Grimmer, G. Henriksen, M. Muhlau, R. Perneczky, I. Miederer, C. Praus, C. Sorg, A. Wohlschlager, M. Riemenschneider, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease Neurology, April 28, 2009; 72(17): 1487 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Minati, T. Edginton, M. Grazia Bruzzone, and G. Giaccone Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review American Journal of Alzheimer's Disease and Other Dementias, April 1, 2009; 24(2): 95 - 121. [Abstract] [PDF] |
||||
![]() |
M. T. Fodero-Tavoletti, C. C. Rowe, C. A. McLean, L. Leone, Q.-X. Li, C. L. Masters, R. Cappai, and V. L. Villemagne Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias J. Nucl. Med., February 1, 2009; 50(2): 198 - 204. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Tolboom, M. Yaqub, W. M. van der Flier, R. Boellaard, G. Luurtsema, A. D. Windhorst, F. Barkhof, P. Scheltens, A. A. Lammertsma, and B. N.M. van Berckel Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET J. Nucl. Med., February 1, 2009; 50(2): 191 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Edison, C C Rowe, J O Rinne, S Ng, I Ahmed, N Kemppainen, V L Villemagne, G O'Keefe, K Nagren, K R Chaudhury, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J. Neurol. Neurosurg. Psychiatry, December 1, 2008; 79(12): 1331 - 1338. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Aizenstein, R. D. Nebes, J. A. Saxton, J. C. Price, C. A. Mathis, N. D. Tsopelas, S. K. Ziolko, J. A. James, B. E. Snitz, P. R. Houck, et al. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly Arch Neurol, November 1, 2008; 65(11): 1509 - 1517. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Gomperts, D. M. Rentz, E. Moran, J. A. Becker, J. J. Locascio, W. E. Klunk, C. A. Mathis, D. R. Elmaleh, T. Shoup, A. J. Fischman, et al. Imaging amyloid deposition in Lewy body diseases Neurology, September 16, 2008; 71(12): 903 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Ikonomovic, W. E. Klunk, E. E. Abrahamson, C. A. Mathis, J. C. Price, N. D. Tsopelas, B. J. Lopresti, S. Ziolko, W. Bi, W. R. Paljug, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain, June 1, 2008; 131(6): 1630 - 1645. [Abstract] [Full Text] [PDF] |
||||






